Düsseldorf University Hospital

Researchers

• IEIrene Esposito
• TLTom Luedde

Running trials

• Not yet recruiting

  Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care

  NCT07699640· Heinrich-Heine University, Duesseldorf· Source

• Not yet recruiting

  A Study to Evaluate Clinical Benefit, Performance and Safety of Cochlear Implants in Adults

  NCT07338864· Cochlear· Source

• Recruiting

  Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy

  NCT07882797· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  GRAnulomatous MAstitis REGistry Study

  NCT07422870· European Breast Cancer Research Association of Surgical Trialists· Source

• Not yet recruiting

  Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis

  NCT07577466· Heinrich-Heine University, Duesseldorf· Source

• Not yet recruiting

  RELIEVE METAB Study

  NCT07555925· Heinrich-Heine University, Duesseldorf· Source

• Not yet recruiting

  Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).

  2025-523672-23-00· Phase 2· UroTrials GmbH· Source

• Recruiting

  Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support

  NCT07655479· University Hospital of Cologne· Source

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Quell Therapeutics Limited· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Philipps University Marburg· Source

• Recruiting

  Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

  NCT07273903· Heinrich-Heine University, Duesseldorf· Source

• Active, not recruiting

  COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)

  NCT07455097· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

  NCT07365930· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps

  NCT06765226· Abiomed Inc.· Source

• Recruiting

  Biological Determinants and Neural Compensation of Dysphagia in Parkinson's Disease

  NCT07299448· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

  NCT07264426· argenx· Source

• Enrolling by invitation

  Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)

  NCT06898086· Rede Optimus Hospitalar SA· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  NCT06782373· Phase 2· Swedish Orphan Biovitrum· Source

• Active, not recruiting

  FARAPULSE Workflow Assessment Registry

  NCT06656884· Boston Scientific Corporation· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Dominik Paul Modest· Source

• Recruiting

  Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

  NCT06764706· AbbVie· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· The Leeds Teaching Hospitals NHS Trust· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer

  NCT06820333· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

  NCT07426991· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

  NCT06780150· Hoffmann-La Roche· Source

• Recruiting

  Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

  NCT06498349· University of Kiel· Source

• Recruiting

  STIMPulseControl Ancillary Speech Study

  NCT06561919· Steffen Paschen· Source

• Recruiting

  Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach

  NCT06501950· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

  NCT06122584· Phase 3· ABX advanced biochemical compounds GmbH· Source

• Recruiting

  Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer

  NCT06474806· Phase 2· Curasight· Source

• Recruiting

  PROCARE - PROstate Cancer Real World Evidence Registry

  NCT06835218· UroTrials Company (GmbH)· Source

• Recruiting

  Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

  NCT06553625· Boston Scientific Corporation· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

  NCT06055725· Ipsen· Source

• Recruiting

  Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer

  NCT06133543· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  The ReTAVI Prospective Observational Registry

  NCT05601453· Institut für Pharmakologie und Präventive Medizin· Source

• Recruiting

  The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

  NCT05427370· Sunnybrook Health Sciences Centre· Source

• Not yet recruiting

  Mesopancreas Study in Pancreatic Cancer

  NCT05895214· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  Home-based Gait and Balance Training in Patients With Movement Disorders

  NCT06617884· Forschungszentrum Juelich· Source

• Recruiting

  DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device

  NCT05543447· Acandis GmbH· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT05471843· Phase 1/2· BeOne Medicines· Source

Showing 50 of 87.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease7 recruiting
• Heart failure5 recruiting
• Prostate cancer5 recruiting
• Childhood cancers4 recruiting
• Coronary artery disease4 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Dystonia3 recruiting
• Essential tremor3 recruiting
• Multiple sclerosis3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Aortic stenosis2 recruiting
• Bladder cancer2 recruiting
• Colorectal cancer2 recruiting
• Pancreatic cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Testicular cancer2 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Brain aneurysm1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Mitochondrial disease1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Ulcerative colitis1 recruiting
• Ventricular tachycardia1 recruiting
• Wilson disease1 recruiting

Closed trials

• Recruiting

  Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  NCT06780111· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· PRInnovation GmbH· Source

• Terminated

  The RECOVER IV Trial

  NCT05506449· Abiomed Inc.· Source

• Completed

  Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia

  NCT05884528· Merz Therapeutics GmbH· Source

• Recruiting

  A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

  NCT05319730· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma

  2022-501463-40-01· Phase 3· Servier Affaires Medicales· Source

• Completed

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Terminated

  KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

  NCT06342960· Phase 1/2· Kyverna Therapeutics· Source

• Active, not recruiting

  A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

  NCT05490446· Phase 2· Agios Pharmaceuticals, Inc.· Source

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Organon and Co· Source

• Completed

  A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

  NCT05342636· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

  NCT05368285· Phase 2· Celldex Therapeutics· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

  NCT04931771· ECRI bv· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Completed

  Combined Active Treatment in Type 2 Diabetes With NASH

  NCT04639414· Phase 4· German Diabetes Center· Source

• Completed

  NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients

  NCT06688149· Fundación Pública Andaluza para la gestión de la Investigación en Sevilla· Source

• Completed

  REcanalization of Distal Cerebral Vessels in Acute Stroke Using ApeRio®

  NCT04479020· Acandis GmbH· Source

• Terminated

  Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

  NCT04261777· Phase 3· Saving Patients' Lives Medical B.V.· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Triple-Negative Breast Cancer

  2022-500418-24-00· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Terminated

  The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO

  NCT04029233· Occlutech International AB· Source

• Completed

  PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

  NCT03996772· Phase 3· Imperial College London· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

  NCT03520946· Phase 3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

  NCT03745287· Phase 2/3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

  NCT03635567· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

  NCT03573310· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System

  NCT03417011· Medtronic Cardiovascular· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· BeiGene· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Boston Scientific Corporation· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· ARCAGY/ GINECO GROUP· Source

• Completed

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· Phase 3· NovoCure GmbH· Source

• Completed

  A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation

  NCT02444338· University Medical Center Goettingen· Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Phase 3· Swiss Cancer Institute· Source

• Completed

  Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

  NCT01644110· Phase 1/2· University of Ulm· Source

• Completed

  SD01 Master Study (Safety and Efficacy Study)

  NCT01836497· Biotronik SE & Co. KG· Source

• Completed

  Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

  NCT01228331· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Type 2 diabetes64 works · 1 trial
• Systemic sclerosis (scleroderma)37 works · 1 trial
• Multiple sclerosis32 works · 3 trials
• Chronic rhinosinusitis with nasal polyps22 works · 1 trial
• Aortic aneurysm20 works · 0 trials
• Myelodysplastic syndromes9 works · 4 trials
• Liver cirrhosis8 works · 0 trials
• Myasthenia gravis8 works · 0 trials
• Neuromyelitis optica (NMOSD)8 works · 0 trials
• Dystonia7 works · 4 trials
• Charcot-Marie-Tooth disease4 works · 0 trials
• Polymyalgia rheumatica4 works · 0 trials
• Friedreich ataxia4 works · 0 trials
• Polycystic kidney disease4 works · 0 trials
• Giant cell arteritis4 works · 0 trials
• Mitochondrial disease3 works · 1 trial
• Testicular cancer3 works · 2 trials